Tate & Lyle opens the week with a clear sector backdrop, shares in the FTSE comparison
Published on 06/29/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 14:31.
Tate & Lyle (GB0008707753) starts the week with a defined role in the European food ingredients space. The London listed group sits in the FTSE 250 alongside peers such as Kerry Group and DSM-Firmenich, giving investors a clear sector frame.
Where Tate & Lyle stands
Tate & Lyle focuses on specialty food ingredients, competing with players like DSM-Firmenich in texture and nutrition and Kerry Group in taste and functional solutions, as sector profiles on European exchanges show. The company continues to emphasize its specialty portfolio following the historic split of its bulk sweeteners business, with current investor material highlighting nutrition and texture platforms.
Sector reports point to stable demand for reformulation ingredients such as fiber enrichment and sugar reduction, areas where Tate & Lyle positions itself as a partner for global food manufacturers. This puts the stock in the same broader functional ingredients narrative that also drives interest in names like Tate & Lyle's listed peers across Europe.
The week’s focus for investors
The Monday focus for many institutional investors is the upcoming corporate calendar, and Tate & Lyle is expected to provide its next trading update in July in line with the usual quarterly rhythm that peers such as Kerry Group and DSM-Firmenich also follow on Euronext and SIX. Consensus data from analyst platforms show that the stock is covered by several UK and European brokerages, with a mixed rating distribution between Buy and Hold on recent screens.
Analyst commentary on the broader food ingredients sector emphasizes margin resilience and cash generation, with recent notes on peers such as DSM-Firmenich citing robust demand for health and nutrition solutions despite cost pressures. Against this backdrop, Tate & Lyle remains part of sector comparisons that look at growth in specialty ingredients versus more commodity exposed models.
Background and price data on Tate & Lyle
All news, regulatory filings and price information on the Tate & Lyle shares are bundled in the dedicated topic section and on the company’s Investor Relations page.
What the company sells
Tate & Lyle generates most of its revenues from specialty food ingredients such as sweeteners, texturants and health and wellness products, according to its latest corporate profile. A representative product line is its low calorie sweeteners and fiber-enriched ingredients used by global beverage and food brands for sugar reduction and digestive health.
Where the shares trade today
The Tate & Lyle shares (GB0008707753) trade on the London Stock Exchange, with the latest verifiable quote data pointing to a listing in sterling without a German Xetra line; detailed intraday prices are available on major UK trading platforms.
Tate & Lyle at a glance
- Company: Tate & Lyle PLC
- ISIN: GB0008707753
- WKN: 855667
- Ticker: TATE
- Trading venue: London Stock Exchange
- Price (as of 2026-06-29, 14:31): not live-verifiable in this check, see UK exchange data
- Market cap: based on recent London data, the company’s equity value is in the mid-single digit billions of pounds
- Sector / industry: Consumer Staples / Food Ingredients
- Index membership: FTSE 250
- Next earnings date: next trading update expected in July 2026 per standard reporting cycle
This article is for informational purposes only and does not contain investment advice, buy or sell recommendations, or price targets. Data and sources are considered reliable but cannot be guaranteed; investors should consult official filings and their own advisers.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
